tiprankstipranks
Advertisement
Advertisement

Junshi Biosciences Chairman Continues Shareholding Increase Plan

Story Highlights
  • Junshi Biosciences’ chairman is executing a 12-month plan to boost his A and H shareholdings by at least RMB100 million, underscoring confidence in the company’s long-term outlook and alignment with investors.
  • So far, chairman Xiong Jun has bought 365,382 A shares for about RMB12.21 million, and he plans to continue increasing his stake as market conditions permit, potentially supporting sentiment toward the stock.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Junshi Biosciences Chairman Continues Shareholding Increase Plan

Claim 30% Off TipRanks

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.

Shanghai Junshi Biosciences announced the latest progress of a previously disclosed plan by chairman and controlling shareholder Xiong Jun to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑month period starting 12 April 2025. The plan allocates no less than RMB50 million to A shares and will be executed via permitted methods on the Shanghai and Hong Kong exchanges, signaling management’s confidence in the company’s long‑term prospects and alignment with minority shareholders.

As of the announcement date, Xiong Jun has acquired 365,382 A shares through centralized bidding on the Shanghai Stock Exchange, representing about 0.04% of the company’s total share capital and involving a total transaction value of approximately RMB12.21 million. The shareholding increase plan remains incomplete, and the chairman intends to continue raising his stake in line with the plan as market opportunities arise, which could support market sentiment toward the stock and reinforce the company’s governance stability.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong, engaged in the research, development and commercialization of innovative medicines. The company operates through A shares on the Shanghai Stock Exchange and H shares on the Hong Kong Stock Exchange, reflecting a focus on both domestic and international capital markets.

Average Trading Volume: 3,093,630

Technical Sentiment Signal: Sell

Current Market Cap: HK$32.13B

For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1